⌕
Novartis · NVS · NYSE
Tenet 55 · Mixed
Compare
$159.13−0.67%At closeTenet 55 · Mixed
$159.13−1.07 (−0.67%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Novartis (NVS) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~6.5%/yr (FY21→FY25), net margin 24.6%, and free cash flow (~$15.2B) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (134%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($B)▲9.6%
56.7
FY21→FY25CAGR +6.5%/yr
Net income ($B)▲16.9%
13.9
FY21→FY25CAGR −12.7%/yr
Free cash flow ($B)▲10.4%
15.2
FY21→FY25CAGR +5.1%/yr
Diluted EPS▲21.8%
7.15
buyback-liftedCAGR −9.4%/yr
What the receipts whisper · what a headline number hides
Share count
−14.6%

2.2bn → 1.9bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

Capex
$3.9B

steady at 6.9% of revenue (+2.3% YoY).

Returns vs FCF
134%

$20.4B returned vs $15.2B of FCF in FY25. The gap comes off the balance sheet (see net cash).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)56.7Revenue−13.7COGS43.0Gross profit−11.2R&D−13.2SG&A17.6Op income−3.7Tax & other13.9Net income

25¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 73.3% → 75.8%. Net margin 24.6% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25 †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
56,674.056,674.051,722.046,660.043,461.043,974.0▲9.6%+6.5%
Cost of revenue
13,699.013,699.012,827.012,472.011,582.011,735.0▲6.8%+3.9%
Gross profit
42,975.042,975.038,895.034,188.031,879.032,239.0▲10.5%+7.5%
Research & development
11,200.011,200.010,022.011,371.09,172.08,641.0▲11.8%+6.7%
Selling, general & admin
13,248.013,248.012,566.012,517.012,193.012,827.0▲5.4%+0.8%
Total operating expenses
25,331.025,331.024,351.024,419.023,933.022,183.0▲4.0%+3.4%
Operating incomefeeds ROC rank
17,644.017,644.014,544.09,769.07,946.010,056.0▲21.3%+15.1%
Other income, net
−1,292.0−1,292.0−904.0−646.0−769.014,474.0——
Pretax income
16,352.016,352.013,640.09,123.07,177.024,530.0▲19.9%−9.6%
Income tax
2,385.02,385.01,701.0551.01,128.01,625.0▲40.2%+10.1%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
13,950.013,950.011,937.014,858.06,955.024,015.0▲16.9%−12.7%
Per share
Diluted EPSbuyback-sensitive
7.157.155.877.103.1710.63▲21.8%−9.4%
Diluted shares (bn)
1.911.911.982.042.122.23▼3.4%−3.9%
Margins
Gross margin69th pct in Healthcare
75.8%75.8%75.2%73.3%73.4%73.3%▲0.6pp+2.5pp
Operating margin
31.1%31.1%28.1%20.9%18.3%22.9%▲3.0pp+8.3pp
Net margin89th pct in Healthcare
24.6%24.6%23.1%31.8%16.0%54.6%▲1.5pp−30.0pp
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-04 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Novartis' revenue last fiscal year?

Novartis reported revenue of $56.7B in fiscal 2025, up 9.6% from fiscal 2024.

What was Novartis' net income?

Novartis reported net income of $13.9B in fiscal 2025, a net margin of 24.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.